Skip to main content
CB

Centenaire Biosciences

Centenaire Biosciences develops targeted biopharmaceuticals for cancer, immune diseases, and neurological disorders using advanced drug discovery techniques. The company focuses on addressing the unmet medical needs in these areas by creating therapies that improve patient outcomes and enhance quality of life.

Founded 2021610+ followers
Updated 20 months ago

Funding

$16.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

B
Funding rounds are not available yet.

Founders

Product

Problem

Many significant diseases, including cancers, immune disorders, and neurological conditions, lack effective treatments, resulting in poor patient outcomes and reduced quality of life. Current therapies often have limited efficacy or severe side effects, highlighting the need for more targeted and innovative approaches.

Solution

Centenaire Biosciences is developing a portfolio of targeted biopharmaceutical therapies designed to address unmet medical needs in cancer, immune diseases, and neurological disorders. The company leverages advanced drug discovery techniques to identify and develop novel therapeutics with improved efficacy and safety profiles. By focusing on the deep disease space, Centenaire Biosciences aims to create treatments that precisely target the underlying mechanisms of disease, leading to better patient outcomes and enhanced quality of life.

Target Audience

The primary target audience includes patients suffering from cancer, immune diseases, and neurological disorders, as well as healthcare providers seeking more effective treatment options.

Features

  • Development of targeted biopharmaceuticals for cancer, immune diseases, and neurological disorders
  • Utilization of advanced drug discovery techniques to identify novel therapeutic targets
  • Focus on creating therapies with improved efficacy and safety profiles
This profile is AI-generated and may contain inaccuracies.